| Year |
Citation |
Score |
| 2020 |
Facompre ND, Rajagopalan P, Sahu V, Pearson AT, Montone KT, James CD, Gleber-Netto FO, Weinstein GS, Jalaly J, Lin A, Rustgi AK, Nakagawa H, Califano JA, Pickering CR, White EA, et al. Identifying predictors of HPV-related head and neck squamous cell carcinoma progression and survival through patient-derived models. International Journal of Cancer. PMID 32478869 DOI: 10.1002/Ijc.33125 |
0.408 |
|
| 2020 |
Facompre ND, Rajagopalan P, Pearson AT, Montone KT, James CD, Gleber-Netto FO, Nakagawa H, White EA, Rustgi AK, Califano JA, Pickering CR, Windle B, Morgan IM, Gimotty PA, Basu D. Abstract A01: HPV+ oral cancer PDXs identify prognostic utility for E2F target gene expression and mutation burden Clinical Cancer Research. 26. DOI: 10.1158/1557-3265.Aacrahns19-A01 |
0.428 |
|
| 2020 |
Facompre ND, Rajagopalan P, Sahu V, Gleber-Netto FO, Califano JA, Pickering CR, Gimotty PA, Basu D. Abstract A03: Predictors of HPV-related head and neck cancer progression identified through patient-derived models Cancer Research. 80. DOI: 10.1158/1538-7445.Camodels2020-A03 |
0.408 |
|
| 2019 |
Basu D, Facompre ND, Gimotty PA, Rajagopalan P, Sahu V, Pearson AT, Califano JA, Netto F, Pickering CR. Identifying adverse molecular features of HPV+ head and neck cancers using patient-derived models. Journal of Clinical Oncology. 37: 6057-6057. DOI: 10.1200/Jco.2019.37.15_Suppl.6057 |
0.405 |
|
| 2018 |
Facompre ND, Harmeyer KM, Sahu V, Gimotty PA, Rustgi AK, Nakagawa H, Basu D. Targeting JARID1B's demethylase activity blocks a subset of its functions in oral cancer. Oncotarget. 9: 8985-8998. PMID 29507668 DOI: 10.18632/Oncotarget.23739 |
0.434 |
|
| 2017 |
Harmeyer KM, Facompre ND, Herlyn M, Basu D. JARID1 Histone Demethylases: Emerging Targets in Cancer. Trends in Cancer. 3: 713-725. PMID 28958389 DOI: 10.1016/J.Trecan.2017.08.004 |
0.379 |
|
| 2017 |
Facompre ND, Sahu V, Montone KT, Harmeyer KM, Nakagawa H, Rustgi AK, Weinstein GS, Gimotty PA, Basu D. Barriers to generating PDX models of HPV-related head and neck cancer. The Laryngoscope. PMID 28561270 DOI: 10.1002/Lary.26679 |
0.385 |
|
| 2016 |
Facompre ND, Harmeyer KM, Sole X, Kabraji S, Belden Z, Sahu V, Whelan K, Tanaka K, Weinstein GS, Montone KT, Roesch A, Gimotty PA, Herlyn M, Rustgi AK, Nakagawa H, et al. JARID1B enables transit between distinct states of the stem-like cell population in oral cancers. Cancer Research. PMID 27488530 DOI: 10.1158/0008-5472.Can-15-3377 |
0.433 |
|
| 2015 |
Facompre N, Belden Z, Gimotty P, Rustgi A, Herlyn M, Nakagawa H, Basu D. Abstract 1517: G0-like cells support an oral cancer stem cell pool by transitioning to a JARID1B-high state Cancer Research. 75: 1517-1517. DOI: 10.1158/1538-7445.Am2015-1517 |
0.426 |
|
| 2013 |
Basu D, Bewley AF, Sperry SM, Montone KT, Gimotty PA, Rasanen K, Facompre ND, Weinstein GS, Nakagawa H, Diehl JA, Rustgi AK, Herlyn M. EGFR inhibition promotes an aggressive invasion pattern mediated by mesenchymal-like tumor cells within squamous cell carcinomas. Molecular Cancer Therapeutics. 12: 2176-86. PMID 23939378 DOI: 10.1158/1535-7163.Mct-12-1210 |
0.373 |
|
| 2012 |
Facompre N, Nakagawa H, Herlyn M, Basu D. Stem-like cells and therapy resistance in squamous cell carcinomas. Advances in Pharmacology (San Diego, Calif.). 65: 235-65. PMID 22959028 DOI: 10.1016/B978-0-12-397927-8.00008-7 |
0.371 |
|
| 2012 |
Facompre ND, Sinha I, El-Bayoumy K, Pinto JT, Sinha R. Remarkable inhibition of mTOR signaling by the combination of rapamycin and 1,4-phenylenebis(methylene)selenocyanate in human prostate cancer cells. International Journal of Cancer. Journal International Du Cancer. 131: 2134-42. PMID 22307455 DOI: 10.1002/Ijc.27468 |
0.471 |
|
| 2010 |
Sinha R, Sinha I, Facompre N, Russell S, Somiari RI, Richie JP, El-Bayoumy K. Selenium-responsive proteins in the sera of selenium-enriched yeast-supplemented healthy African American and Caucasian men. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 19: 2332-40. PMID 20643827 DOI: 10.1158/1055-9965.Epi-10-0253 |
0.343 |
|
| 2010 |
Facompre ND, El-Bayoumy K, Sun YW, Pinto JT, Sinha R. 1,4-phenylenebis(methylene)selenocyanate, but not selenomethionine, inhibits androgen receptor and Akt signaling in human prostate cancer cells. Cancer Prevention Research (Philadelphia, Pa.). 3: 975-84. PMID 20606040 DOI: 10.1158/1940-6207.Capr-10-0054 |
0.466 |
|
| 2010 |
Facompre N, Sinha I, Pinto J, El-Bayoumy K, Sinha R. Abstract 574: 1,4-phenylenebis(methylene)selenocyanate (p-XSC) inhibits mammalian target of rapamycin complex 2 (mTORC2) signaling in prostate cancer cells Cancer Research. 70: 574-574. DOI: 10.1158/1538-7445.Am10-574 |
0.481 |
|
| 2009 |
Facompre N, El-Bayoumy K. Potential stages for prostate cancer prevention with selenium: implications for cancer survivors. Cancer Research. 69: 2699-703. PMID 19318549 DOI: 10.1158/0008-5472.Can-08-4359 |
0.415 |
|
| 2008 |
Sinha R, Pinto JT, Facompre N, Kilheffer J, Baatz JE, El-Bayoumy K. Effects of naturally occurring and synthetic organoselenium compounds on protein profiling in androgen responsive and androgen independent human prostate cancer cells. Nutrition and Cancer. 60: 267-75. PMID 18444160 DOI: 10.1080/01635580701630479 |
0.453 |
|
| 2007 |
Pinto JT, Sinha R, Papp K, Facompre ND, Desai D, El-Bayoumy K. Differential effects of naturally occurring and synthetic organoselenium compounds on biomarkers in androgen responsive and androgen independent human prostate carcinoma cells International Journal of Cancer. 120: 1410-1417. PMID 17205524 DOI: 10.1002/Ijc.22500 |
0.446 |
|
| Show low-probability matches. |